Loading...
XOSL
NAVA
Market cap51mUSD
Dec 05, Last price  
21.60NOK
1D
-0.46%
1Q
0.00%
Jan 2017
114.43%
IPO
40.45%
Name

Navamedic ASA

Chart & Performance

D1W1MN
XOSL:NAVA chart
P/E
401.55
P/S
0.97
EPS
0.05
Div Yield, %
Shrs. gr., 5y
8.55%
Rev. gr., 5y
23.00%
Revenues
531m
+3.80%
4,431,931386,45131,835,47846,105,18752,593,12155,092,14371,299,22288,683,865151,772,586223,067,740248,348,362274,297,760257,920,665184,021,794188,754,922209,877,000278,439,000382,135,000511,997,000531,436,000
Net income
1m
-60.96%
-4,866,663-7,572,040-3,211,794-8,076,59912,815,855-11,187,617-7,159,041-3,254,949-1,267,9991,306,185-10,931,730-10,658,412-15,542,4617,283,775-16,297,223-16,460,000618,00029,432,0003,304,0001,290,000
CFO
39m
+1,706.06%
-3,114,131-10,740,7465,557,727-10,660,689-1,646,961-13,463,669-95,521-6,473,430-15,650,876-10,748,49922,628,650-14,508,25159,073,633-36,023,97812,722,136-3,180,000-1,300,00017,941,0002,179,00039,354,000
Dividend
Apr 13, 20101 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
IPO date
Mar 31, 2006
Employees
45
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT